- Home
- TWIN vs CHRS Comparison
TWIN vs CHRS Comparison
Compare TWIN & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TWIN | CHRS |
|---|---|---|
| Founded | 1918 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.5M | 186.0M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | TWIN | CHRS |
|---|---|---|
| Price | $15.33 | $1.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $12.00 | $4.51 |
| AVG Volume (30 Days) | 24.8K | ★ 1.1M |
| Earning Date | 02-04-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.05% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.02 | ★ 1.34 |
| Revenue | ★ $347,837,000.00 | $277,728,000.00 |
| Revenue This Year | $10.79 | N/A |
| Revenue Next Year | $8.43 | $67.29 |
| P/E Ratio | $826.62 | ★ $1.01 |
| Revenue Growth | 14.24 | ★ 152.07 |
| 52 Week Low | $6.16 | $0.71 |
| 52 Week High | $17.08 | $1.89 |
Technical Indicators
Market Signals| Indicator | TWIN | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 51.17 | 53.44 |
| Support Level | $15.28 | $1.18 |
| Resistance Level | $16.09 | $1.45 |
| Average True Range (ATR) | 0.59 | 0.09 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 56.87 | 77.34 |
Price Performance
Historical ComparisonAbout TWIN Twin Disc Incorporated
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.